Next-generation HIV immunotherapy: TCR technology

Applications: T cell receptor (TCR) therapy, Engineered T cells, HLA-E restricted immunity, HIV-1 treatment

Our breakthrough technology harnesses the body’s immune power to fight HIV at its source.

Features	Benefits
Smart HIV Targeting	Our T-cell receptors (TCRs) are designed to recognise hidden HIV fragments presented by a unique immune molecule (HLA-E). This helps overcome HIV’s ability to hide and mutate, offering broader protection across patients.
Precision-Engineered Receptors	Each TCR is built from well-defined genetic sequences, ensuring consistent quality, predictable performance, and easier regulatory approval.
Gene-Based Delivery	We use advanced DNA or RNA vectors to insert these TCRs into immune cells. This allows efficient, scalable manufacturing of patient-ready cell therapies.
Engineered Immune Cells	T cells equipped with our TCRs can seek out and destroy HIV-infected cells—potentially leading to long-term viral control or even functional cure.
Transformative HIV Treatment Potential	Designed to work alongside or beyond antiretroviral therapy (ART), this approach could redefine how HIV is managed and move us closer to ending the epidemic.

Patent pending and available for:

Request more information
about this technology

Technologies for License